Bionomics
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
200 Greenhill Rd, Eastwood, South Austra...Phone Number
+61 881507400Website
www.bionomics.com.auRevenue
<$5 MillionStock Symbol
BNOXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Bionomics
Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (CNS) disorders.Explore more
Bionomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bionomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Bionomics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Bionomics recently announced quarterly report
Funding: Get notified immidiatlly once Bionomics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Bionomics
Product Launch: Get notified when Bionomics launches new products
Check if Bionomics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Bionomics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Bionomics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Bionomics
Find 2 more new buyers
Compare Similar Companies to Bionomics
Compare insights from companies similar to Bionomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bionomics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bionomics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bionomics.
Bionomics financials insights
Gather financial insights about Bionomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Private Equity
$638K
Stock Offering
$17.5M
2024
Other Financing Round
$70M
Bionomics Tech Stack
A closer look at the technologies used by Bionomics
See more technologies
Most Recent Scoops
Earnings
Partnership, Asset Management, Business Intelligence, Product Development, Sales, Business Development, Legacy Systems, Business Finance, Business Insurance, Finance, Operations
Earnings
Earnings
Business Intelligence, Sales, Business Development, Business Finance, Business Insurance, Finance, Operations
Earnings
Earnings
Big Data, Data Center, Database, Infrastructure, Data Management, Data Science, Data Warehousing
Bionomics News & Media
Results of Scheme Meeting
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterBionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in theBionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, is reminding Shareholders to cast their vote in favor of the Scheme Implementation Agreement to re-domicile Bionomics from Australia to the U.S.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Bionomics
Sign Up For FreeTo access detailed company insights
Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (CNS) disorders.... Read More
